hVIVO: Numbers starting to stack up, says broker

hVIVO PLC faces pressure to meet its 2025 revenue forecast of £73 million, a £10 million increase from the previous year, with a significant portion of the revenue dependent on second-half performance. While Panmure Liberum maintains a Buy rating and a 24p price target based on the company's multiple of 7.3 times 2025 enterprise value to EBITDA, potential delays in trial greenlighting due to US healthcare policy uncertainties pose a risk, particularly concerning the ILiAD Biotechnologies LOI; successful contract newsflow in the coming months is crucial to realizing the company's plan.

Analysis

hVIVO PLC is targeting £73 million in revenue for 2025, an increase from £63 million in the prior year, but faces the challenge of securing approximately £21.9 million in 'go-get' revenue, equivalent to 30% of its target, with a significant portion anticipated in the second half of the year. Broker Panmure Liberum views this revenue target as realistic. Key identified contributors to bridging this gap include an anticipated £4 million from change orders on existing trials and a potential £2.5 million from a letter of intent with ILiAD Biotechnologies, although the latter is contingent on funding. Panmure Liberum suggests that the company's comprehensive suite of tools and channels—encompassing hLAB, Site Services, the recently acquired Cryostore, rapid-cycle consulting contracts, and new capabilities from the CRS acquisition—are collectively expected to secure the outstanding revenue, specifically focusing on a crucial £7.8 million portion required to meet the full-year forecast. However, the company's ability to convert these opportunities is subject to external headwinds from political and budgetary uncertainties in the US healthcare landscape, such as FDA budget cuts and NIH funding pressures, which are reportedly causing decision-making hesitancy across the sector, a sentiment echoed by other CROs like Lonza and IQVIA. These factors could potentially delay trial initiations, pushing revenues beyond 2025, with the ILiAD contract highlighted as a specific watch item. Despite these execution risks, hVIVO is forecast to generate £12.4 million in EBITDA in 2025, heavily weighted towards the second half, and maintains a robust financial position with net cash of £26 million. The stock's valuation is considered attractive, trading at 7.3 times 2025 enterprise value to EBITDA, with an expected dividend yield over 1.3%, and a forward multiple projected to drop below 5 by 2026. Panmure Liberum maintains a Buy rating with a 24p price target, implying approximately 40% upside, contingent on successful execution and positive contract newsflow in the coming months.

Key Decisions for Investors

• Investors should closely monitor hVIVO's contract announcements, particularly progress on the ILiAD Biotechnologies LOI and new business secured through CRS, as these will be key indicators of its ability to meet the H2-weighted 2025 revenue guidance.
• The current valuation appears to incorporate a degree of execution risk, offering potential upside if targets are met, but requires investor patience given the back-loaded nature of revenue conversion and inherent uncertainties in contract-driven businesses.
• Consider the impact of US healthcare policy developments on hVIVO's clients, as continued funding pressures or regulatory shifts could delay trial commencements and impact revenue recognition timelines for 2025.